EViS Bioscience Featured in Milano Finanza for Upcoming Capital Raise
EViS Bioscience has been featured in Milano Finanza in relation to its upcoming capital increase, aimed at accelerating the development of its proprietary RNA delivery platform.
The article outlines how the company is addressing one of the most critical challenges in RNA therapeutics: achieving precise, efficient, and safe delivery of genetic material to target cells. EViS Bioscience’s technology focuses on enhancing targeting specificity and biological compatibility, with the goal of improving therapeutic outcomes while reducing unintended effects.
The planned capital raise represents a key step in supporting further preclinical development and scaling activities, as well as strengthening the company’s position within the European biotech landscape. It also reflects increasing investor interest in advanced RNA delivery systems, recognized as a fundamental component for the next generation of precision therapies.
The full article is available on Milano Finanza.
